XBiotech
XBIT
37 hedge funds and large institutions have $14M invested in XBiotech in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 4 closing their positions.
0.47% less ownership
Funds ownership: 11.44% → 10.98% (-0.47%)
5% less funds holding
Funds holding: 39 → 37 (-2)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
32% less capital invested
Capital invested by funds: $20.7M → $14M (-$6.71M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $22K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$205K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$62.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$47.8K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$24K |
| 5 |
EF
Empowered Funds
Havertown,
Pennsylvania
|
+$22.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$257K |
| 2 |
Millennium Management
New York
|
-$142K |
| 3 |
Two Sigma Advisers
New York
|
-$81.1K |
| 4 |
Jane Street
New York
|
-$78.5K |
| 5 |
Two Sigma Investments
New York
|
-$71.1K |
XBIT Hedge Fund Activity: Q3 2023 in Review
37 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q3 2023, worth a combined $14M — down 32% from $20.7M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of XBIT and 3 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 9 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $205K. The largest seller was Man Group, exiting entirely with an estimated $257K sold.
- 37 institutional investors held XBiotech (XBIT) as of Q3 2023, down from 39 in Q2 2023.
- Funds reported $14M of XBiotech stock for Q3 2023, down 32% quarter-over-quarter.
- 3 funds opened new XBiotech positions in Q3 2023 and 4 closed out, a net change of -1 holder.
- The largest XBiotech buyer in Q3 2023 was Susquehanna International Group, an estimated $205K added.
- The largest XBiotech seller in Q3 2023 was Man Group, an estimated $257K sold.
Based on aggregated 13F filings for Q3 2023.